A world-class management team with over 100 years of combined experience in gene therapy, rare disease drug development and commercialization, and biologics manufacturing.
Previously Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. from 2013 through its acquisition by Horizon Pharma, plc in May 2015. From 2010-2013, Ms. Holles provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies. Earlier in her career, Ms. Holles served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and previously held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc.
Ms. Holles is a member of the Board of Directors for Rubius Therapeutics, Inc. She holds an M.A. in Molecular, Cellular, and Developmental Biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow, and an A.B. in Human Biology from Stanford University.
Thomas Soloway is Executive Vice President and Chief Operating Officer at Audentes Therapeutics. He joined the company as Senior Vice President and Chief Financial Officer (CFO) in October 2015 and was appointed Executive Vice President and CFO in April 2019. Mr. Soloway brings to this role more than 25 years of experience in operations, corporate finance, and venture capital in the life sciences industry.
Previously, Mr. Soloway served as the Senior Vice President, Chief Financial Officer of Ascendis Pharma A/S, a Danish biopharmaceutical company. Prior to Ascendis, Mr. Soloway co-founded Transcept Pharmaceuticals, Inc. At Transcept, Mr. Soloway held positions of increasing responsibility, serving initially as Senior Vice President, Operations and Chief Financial Officer and over time as Executive Vice President, Chief Operating Officer. In this role he oversaw project planning, manufacturing, pharmaceutical sciences, legal, human resources, regulatory, and corporate communications. Prior to joining Transcept, Mr. Soloway financed and advised early stage healthcare and life sciences companies as a Principal at Montreux Equity Partners, a venture capital firm.
Mr. Soloway earned a B.S. in Entrepreneurial Studies from the University of Southern California and an M.B.A. from Georgetown University.
Dr. Conner joins Audentes from Sangamo Therapeutics, Inc. where he served as Senior Vice President and Chief Medical Officer and led the clinical development of the company’s pipeline of genomic therapies. Prior to Sangamo, Ed served as Vice President, Global Clinical Development at Ultragenyx Pharmaceutical Inc. where he led the global clinical development efforts for two of the company’s rare disease product candidates. Previously, Ed served as Senior Medical Director at BioMarin Pharmaceutical Inc. where he led clinical development and regulatory interactions for its global Phase 3 program in Pompe disease, and earlier in his career Dr. Conner served as Medical Director at Genentech, Inc. where he was the clinical science team leader of two product candidates, including XOLAIR®.
Dr. Conner completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco.
Eric B. Mosbrooker has served as Senior Vice President and Chief Commercial Officer (CCO) at Audentes Therapeutics since January 2019. He brings more than 15 years of healthcare leadership experience focused on launching and commercializing treatments for rare and orphan diseases. As CCO, Mr. Mosbrooker is responsible for executing the global commercial strategy for the company’s growing portfolio of gene therapy product candidates, and for building the commercial organization, including patient services, sales, marketing, and market access teams.
Mr. Mosbrooker joined Audentes from Origin Biosciences, a subsidiary of BridgeBio Pharma and a biotechnology company focused on developing a treatment for molybdenum cofactor deficiency (MoCD) type A, a rare pediatric metabolic disorder, where he served as Chief Operating Officer. Prior to Origin Biosciences, Mr. Mosbrooker led the orphan business at Horizon Pharma after its acquisition of Raptor Pharmaceuticals. At Raptor, he was the Senior Vice President of Americas & Asia Pacific, where he led the U.S. launch of Procysbi®, a drug for the treatment of nephropathic cystinosis. Previously, Mr. Mosbrooker served as the lead for commercial operations and market access for Strensiq® at Alexion and Enobia Pharma, Inc. He also served in various commercial operational capacities at Onyx Pharmaceuticals, Jazz Pharmaceuticals Inc., Chiron Corporation (now Novartis), and Millennium Pharmaceuticals. Additionally, he has extensive experience in management, healthcare, and technology consulting at IBM, Teltech Resource Network Corporation, and Kohler Company. Mr. Mosbrooker earned his B.S. in Industrial Engineering from the University of Wisconsin, Madison.
Fulvio Mavilio, Ph.D. is Senior Vice President of Translational Science at Audentes Therapeutics. He joined the company as Vice President Scientific Affairs, Europe in July 2017. A highly regarded expert and pioneer in the gene therapy field, Dr. Mavilio is responsible for advancing the company’s pipeline from discovery to clinical development overseeing molecular biology, in vivo pharmacology, bioinformatics, and bioanalytics at Audentes.
Prior to joining Audentes, Dr. Mavilio served as Chief Scientific Officer of Genethon in Evry, France from 2012 to 2017 where he led the development of a robust pipeline of gene therapy programs for blood, liver, and neuromuscular diseases. Previously, he was co-Director of the Center for Regenerative Medicine of the University of Modena, Italy from 2006 to 2011, Director of Discovery of Molmed SpA from 2002 to 2005, founder and Chief Scientific Officer of Genera SpA from 1999 to 2002, and co-Director of the San Raffaele-Telethon Institute of Gene Therapy in Milan, Italy from 1995 to 2002. Under these tenures, he designed and developed gene therapies for inherited and acquired diseases, including the pioneer treatment for adenosine deaminase deficiency that became the first ex vivo gene therapy to receive marking authorization in Europe.
Dr. Mavilio is a member of the European Molecular Biology Association (EMBO), past member of the Board of the American Society of Gene and Cell Therapy (ASGCT), and a member of the Editorial Board of many international journals in the fields of genetics, molecular biology, and gene therapy. He earned an undergraduate degree in Biology at the University of Rome in 1976 and a Ph.D. in Medical Genetics at the University of Rome School of Medicine in 1979. He also trained as a visiting scientist at the Wistar Institute in Philadelphia, PA from 1985 to 1989. Dr. Mavilio has published more than 190 articles in major international journals. He also serves as Professor of Molecular Biology at the University of Modena and Reggio Emilia in Modena, Italy.
Mary Newman is Senior Vice President of Regulatory Affairs at Audentes Therapeutics. She joined the company with more than 20 years of experience in regulatory affairs and research and development within the biotechnology industry, focusing on rare diseases. Ms. Newman oversees global regulatory strategic development, all primary regulatory agency interactions, and regulatory compliance for Audentes’ development candidates.
Prior to joining Audentes, Ms. Newman served as the Senior Vice President, Regulatory Affairs and Quality Assurance at SARcode Bioscience Inc., which was acquired by Shire Ltd. She previously held various management positions, with increasing responsibility in Regulatory Affairs at BioMarin Pharmaceutical, Inc., Berlex Inc. (now Bayer HealthCare Pharmaceuticals Inc.), and Sequus Pharmaceuticals, Inc. (now Johnson & Johnson). While at BioMarin, Ms. Newman oversaw the development and approval of Kuvan® for the treatment of phenylketonuria (PKU), Naglazyme® for mucopolysaccharidosis (MPS) VI, and supported the final approval of Aldurazyme® for MPS I. She has also held various research and development leadership roles in oncology, neurology, and antifungal therapeutic areas.
Ms. Newman holds a B.S. in Physiology from Oregon State University.
Donald Wuchterl has served as Senior Vice President of Technical Operations at Audentes Therapeutics since January 2016. He is responsible for the company’s Quality, Manufacturing, Supply Chain, Facilities & Engineering, and Process & Analytical Development teams.
Mr. Wucheterl has more than 25 years of experience in manufacturing clinical and commercial GMP products including biologics, small molecules, cellular immunotherapies, and AAV gene therapies. Mr. Wuchterl has extensive experience in the design, buildout, validation, licensure, and operation of these facilities.
Mr. Wuchterl joined Audentes from Cytovance Biologics where he was Senior Vice President and Chief Operating Officer. Prior to Cytovance, Mr. Wuchterl held positions of increasing responsibility in manufacturing and operations-related roles at Dendreon, Shire HGT, Amgen, Biogen Idec, and Roche.
Mr. Wuchterl holds a B.S. in Business Administration from Colorado Technical University and a M.B.A. from Fitchburg State University.
Previously Ms. Baierlein served as Executive Director, Program Management at Ultragenyx Pharmaceutical Inc. from 2013 through 2018. From 2009 through 2013, Ms. Baierlein held management positions at BioMarin in both program management and clinical operations. Earlier in her career, Ms. Baierlein held roles of increasing responsibility at Genentech, Inc and Elan Pharmaceuticals.
Ms. Baierlein holds an B.S. in Biology and Kinesiology from the University of Minnesota.
Lovena D. Chaput is Senior Vice President, Americas at Audentes Therapeutics. She joined the company in December 2019 as Senior Vice President of Global Market Access. She brings more than 30 years of healthcare leadership experience focused on launching and commercializing treatments for rare and orphan diseases in startup organizations. As Senior VP Market Access, Ms. Chaput is responsible for executing the global market access strategy for the company’s growing portfolio of gene therapy product candidates, and for building the commercial market access organization, including distribution, patient services and market access teams.
Ms. Chaput joined Audentes from AveXis, a Novartis company, where she served as VP, Market Access and Reimbursement. During her tenure with AveXis she led the highly successful launch of ZOLGENSMA®, the first gene therapy for Spinal Muscular Atrophy. Prior to AveXis, Ms. Chaput was with Raptor Pharmaceuticals where she was the Executive Director, Commercial Operations, Americas & Asia Pacific. While at Raptor, she led the U.S. Market Access strategy and launch of Procysbi®, a drug for the treatment of nephropathic cystinosis. Previously, Ms. Chaput designed and built the commercial organization for Amylin Pharmaceuticals. During her tenure at Amylin she held various strategic and leadership roles in sales, marketing, trade and distribution, and market access, launching several first in class products, including Symlin®, Byetta® and BYDUREON®. Ms. Chaput also served in various commercial roles at Raptor, Amylin, Bristol-Myers Squibb and Syntex Laboratories, Inc. Ms. Chaput holds a B.S. in Biology from Willamette University in Salem, Oregon.
Jason O’Byrne is Senior Vice President of Finance at Audentes Therapeutics. He brings more than 20 years of global finance and operations experience across R&D, business development, manufacturing and commercial. Mr. O’Byrne is responsible for leading all aspects of the finance organization, leveraging his experience to prepare the team and systems for future commercial operations
Mr. O’Byrne joined Audentes in April 2019 as Vice President of Finance and was appointed to his current position in March 2020. He joined Audentes from Roche Pharmaceuticals, where he held positions of increasing responsibility, most recently serving as Asia Pacific Head of Finance, based in Singapore. Prior to that, Mr. O’Byrne held finance leadership positions at Genentech and Roche across product development, research, supply chain, and business development for over 13 years. Earlier in his career, Mr. O’Byrne was a controller with General Chemical and an engineer with General Motors
Mr. O’Byrne holds a Bachelor of Applied Science in Mechanical Engineering from the University of British Columbia, and an M.B.A. in Finance from New York University.
Ms. Person joined Audentes in April 2020 from Sangamo Therapeutics, Inc. where she served as Head of Human Resources. Prior to Sangamo, Julie was the Global Head of Talent Management at Shire Plc. where she led talent management, culture and employee experience, and also played a key role in the integrations of both Baxalta International Inc. to Shire, and Shire into Takeda Pharmaceutical Company Ltd. Prior to Shire, Julie spent 12 years at McKesson Corp. in various HR roles of increasing responsibility.
Ms. Person earned her B.A. in Communications from Saint Mary’s College of California.